ArticleThe pharmacogenomics journal
Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine.
Article in The pharmacogenomics journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.Ontario health technology assessment series · 2021Pooled it
- Exploratory Association of 5' and 3' UTRs Variants inInternational journal of molecular sciences · 2026Article
- 23andYOU: How Pharmacogenomics Is Important to You and Your Patients.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Review
- The Case for Pre-Emptive Pharmacogenetic Screening in South Africa.Journal of personalized medicine · 2024Article
- Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1.Experimental biology and medicine (Maywood, N.J.) · 2024Article
- Pharmacogenetics of Anticancer Drugs: Clinical Response and Toxicity.Cancer treatment and research · 2023Article
- Pharmacists' Knowledge, and Insights in Implementing Pharmacogenomics in Saudi Arabia.International journal of environmental research and public health · 2022Article
- Novel MicroRNA-Regulated Transcript Networks Are Associated with Chemotherapy Response in Ovarian Cancer.International journal of molecular sciences · 2022Article
- Epi-Drugs in Heart Failure.Frontiers in cardiovascular medicine · 2022Review
- Article
- Genetics of Food Allergy.Immunology and allergy clinics of North America · 2021Review
- The Gene-Drug Duality: Exploring the Pharmacogenomics of Indigenous Populations.Frontiers in genetics · 2021Review
- Nursing Personnel in the Era of Personalized Healthcare in Clinical Practice.Journal of personalized medicine · 2020Review
- Physicians' Attitudes and Ethical Obligations to Pharmacogenetic Testing.Journal of multidisciplinary healthcare · 2020Article
- Towards precision medicine: interrogating the human genome to identify drug pathways associated with potentially functional, population-differentiated polymorphisms.The pharmacogenomics journal · 2019Article
- Pharmacogenomics, CYP2D6, and Tamoxifen: A Survey of the Reasons Sustaining European Clinical Practice Paradigms.Medicina (Kaunas, Lithuania) · 2019Article
- On the readiness of physicians for pharmacogenomics testing: an empirical assessment.The pharmacogenomics journal · 2018Article
- A question of fate.PLoS biology · 2017Article
- Individualized medicine enabled by genomics in Saudi Arabia.BMC medical genomics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenetics arose with studies of single genes, which had major effects on the action of particular drugs. It turned into pharmacogenomics through realization that the controls of most drug responses are multifactorial. Then, variable gene expression posed new problems, for example what do drugs do to genes, or how useful is any genetic pretesting of a person? A common disease may be caused by different groups of genes in different people, who therefore require different drugs for treatment. Personalized medicine is currently represented by a physician's attention to a patients age, sex, or ethnic background, that is groups showing smaller genetic variation than is typical for general humanity. Occasionally, there is also the use of single-gene pretesting of a patient before drug administration. Over time, improvements in multigenic testing promise to increase the role of personalized medicine. However, the many pharmacogenomic complexities, and particularly time-dependent changes of gene expression, will never allow personalized medicine to become an error-free entity.
Indexed as
Identifiers
16415920What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.